PVA TePla: an AI-inspection business with an earnings problem (?)

PVA TePla: an AI-inspection business with an earnings problem (?) Note: Sources come from https://chilterncap.substack.com/p/pva-tepla-scanning-acoustic-microscopy. I am long PVA TePla because I think its semiconductor-inspection business can become substantially larger and more profitable than the current group earnings suggest. The complication is that “can become” and “currently is” are different things, and the company’s latest results demonstrate the distinction quite effectively. PVA is a German equipment manufacturer, traded as **TPE on Xetra / TPE.DE**. It has two businesses: **Metrology**, which measures and inspects materials and semiconductor components, and **Material Solutions**, which supplies equipment for producing and processing advanced materials. Our thesis is that growth in semiconductor inspection can change the group’s earnings mix, while a recovery in materials equipment can remove an existing drag. The additional short-interest angle is interesting, but it comes second. A share register is not a business model. # What does PVA actually sell? Start with the inspection business. Advanced semiconductor packaging increasingly involves connecting and stacking components rather than putting everything on one piece of silicon. High-bandwidth memory, or HBM, stacks memory dies vertically. More elaborate packages bring together logic, memory and connecting structures. That creates a manufacturing problem: the components can be individually good while the assembled structure contains a defect. A void, crack or separation between bonded layers can compromise the finished product. Looking at its surface does not necessarily tell you what is happening underneath. PVA’s **scanning acoustic microscopy**, or SAM, uses high-frequency ultrasound to inspect internal structures without cutting the component apart. It sends sound into the sample and interprets the returning signals. Changes in the material—including air gaps and delamination—produce different reflections. The result is an image of structures that ordinary surface inspection cannot reveal. The economic proposition is straightforward. The more value a manufacturer has accumulated in a complex package, the more expensive it becomes to discover a manufacturing defect late. Inspection equipment helps identify problems and improve the process before more value is committed. PVA does not need to design the winning AI processor. It needs to sell useful equipment to the people trying to manufacture advanced semiconductor products reliably. This is a less glamorous role than designing the processor, but customers generally prefer their expensive chips without hidden manufacturing defects. # Why would this become a better business? There are two separate arguments, and it is important not to merge them. The first is **market growth**. More advanced packaging and HBM production can create more inspection work. The second is **PVA’s ability to capture that work profitably**. That depends on customer qualifications, equipment performance, production capacity, service and competition—not merely on whether AI spending increases. A production customer needs more than a microscope that produces an impressive image. It needs sufficient resolution at an acceptable inspection speed, repeatable results, automated handling and dependable support. Our investment case depends on PVA earning and retaining those production roles. Once equipment is embedded in a manufacturing process, the commercial opportunity can extend beyond the initial sale to servicing, spare parts and upgrades. PVA offers those lifecycle services, but that does not make the whole business recurring revenue. It remains an equipment supplier exposed to customer investment cycles. [PVA’s products and service offering](https://www.pvatepla.com/products-technologies/advanced-packaging-inspection/). There is also an important correction to the more enthusiastic version of the thesis: **more layers do not automatically mean proportionately more machines**. PVA itself describes systems capable of inspecting multiple layers simultaneously. Inspection recipes, sampling rates, throughput improvements and the number of qualified process steps all affect equipment demand. A chart multiplying wafer production by stack height can illustrate potential inspection complexity. It cannot, by itself, forecast PVA’s revenue. [SAM Auto Panel](https://www.pvatepla.com/products-technologies/wafer-inspection/scanning-acoustic-microscopy/sam-auto-panel/) That distinction matters. We want exposure to a growing inspection requirement, not an investment thesis dependent on manufacturers refusing to improve productivity. # The other business is not just an inconvenient furnace division Material Solutions supplies equipment for crystal growth and other advanced-material processing, including sintering, diffusion bonding and brazing. Its applications extend beyond semiconductors into industrial markets. [PVA’s technology portfolio](https://www.pvatepla.com/corporate/investor-relations/news/pva-tepla-hosts-successful-capital-markets-day-2025-and-provides-strategic-outlook/) This part of PVA is more exposed to project timing and equipment-investment cycles. When customer projects move, revenue moves with them, while the manufacturer still has employees, facilities and development costs. But describing it purely as a silicon-carbide recovery bet misses another development: **indium phosphide**. PVA has received orders for equipment used to grow indium-phosphide crystals. The company identifies optical data transmission in AI data centres as an important application. That gives Material Solutions another route into AI infrastructure, distinct from inspecting HBM. In H1 2026, Material Solutions orders rose to **€89.0 million from €50.3 million**, even though revenue fell to **€67.6 million from €75.4 million**. The company specifically highlighted indium-phosphide equipment among the order drivers. [Company H1 release](https://www.pvatepla.com/de/corporate/investor-relations/finanznachrichten/pva-tepla-mit-hohem-auftragseingang-und-verbesserter-geschaeftsent-wicklung-im-zweiten-quartal-2026/) That is the underlying pattern across PVA: demand is arriving faster than it is appearing in reported revenue and profit. The investment question is whether this is a timing gap or a persistent problem converting orders into attractive economics. # The orders support the thesis. The margins challenge it. Metrology’s H1 orders reached **€97.7 million**, up approximately **83%**. Revenue increased **20% to €53.0 million**. That produces a calculated segment book-to-bill of approximately **1.84 times**: significantly more orders booked than revenue recognised during the period. It is not a growth forecast, but it is stronger evidence than an addressable-market slide. [Company H1 release](https://www.pvatepla.com/de/corporate/investor-relations/finanznachrichten/pva-tepla-mit-hohem-auftragseingang-und-verbesserter-geschaeftsent-wicklung-im-zweiten-quartal-2026/) Management also reports that existing metrology production lines are fully booked for H1 2027, with additional lines under construction filling up. That supports the argument that the opportunity extends beyond a single quarter. It remains management’s description of demand visibility, not a guarantee of delivery or profitability. [H1 presentation](https://www.pvatepla.com/fileadmin/sitepackage/pdf/Pr%C3%A4sentationen/PVA_TePla_Presentation_H1_2026.pdf) Now the uncomfortable part. Despite that revenue growth, Metrology’s H1 EBITDA fell to **€5.8 million from €8.7 million**. Its EBITDA margin declined from **19.7% to 10.9%**. Group H1 EBITDA fell to **€4.4 million from €14.9 million**. The company identifies lower utilisation, higher operating expenses, service-infrastructure expansion and other effects among the pressures. [H1 report](https://www.pvatepla.com/fileadmin/sitepackage/pdf/investor_relations/berichte/2026/PVATePla_Half-Year_Report_2026.pdf) So the shorts have a real argument. “Orders are strong” does not answer “why are profits weak?” The bullish explanation is that PVA is building the capacity and organisation needed for a larger business, incurring costs before the associated revenue arrives. The bearish explanation is that the business requires more expense, more time or less attractive pricing than the original model assumed. Both explanations are consistent with strong orders and weak current earnings. Subsequent results have to distinguish between them. Calling an expense “investment” is a reasonable description of management’s intention; it is not an accounting entry for future success. # What needs to happen next? Management expects 2026 EBITDA in the **lower half of its €26–31 million range**, with Q4 making the largest contribution to revenue and earnings. It also expects Q3 profitability to improve, with the EBITDA margin approaching double digits. [H1 presentation](https://www.pvatepla.com/fileadmin/sitepackage/pdf/Pr%C3%A4sentationen/PVA_TePla_Presentation_H1_2026.pdf) Taking “lower half” arithmetically as approximately **€26–28.5 million**, and subtracting H1’s €4.4 million, leaves **€21.6–24.1 million to earn in H2**. In other words, approximately **83–85% of the implied full-year EBITDA still needs to arrive in the second half**. That is the execution hurdle. It explains why a strong order announcement and an uncomfortable share-price reaction can coexist without either the market or management necessarily being irrational. Our fundamental long case is that shipments catch up with orders, the expanded cost base is spread over more revenue, and Metrology’s growing contribution improves group economics. A recovery in Material Solutions would help rather than leaving Metrology to carry the entire company. What would weaken that case is equally clear: repeated shipment deferrals, further guidance reductions, continued margin deterioration despite revenue growth, or revenue that fails to convert into cash. The evidence we want is better earnings conversion—not another quarter in which the backlog is excellent company for the shareholders’ unrealised losses. # What could the business be worth? Valuation scenarios are **€43 base, €91 bull and €173 super-bull**, using operating forecasts extending through FY2030. From €28.50, those represent approximately **51%, 219% and 507% upside**. The base assumes revenue reaching approximately **€403 million**, with a **19.7% EBITDA margin**. The bull assumes approximately **€526 million** and **28.1%**. The super-bull assumes approximately **€652 million** and **34.6%**. These are the original published assumptions, not newly validated forecasts. The distinction between those cases is not simply how excited investors become about AI. It is how much revenue PVA generates, how much becomes operating profit, and what valuation investors assign to those earnings. For context, management’s published medium-to-long-term EBITDA-margin ambition is **20–25%**. The bull and super-bull assumptions therefore require performance above that range. They should be understood as aggressive scenarios, not ordinary delivery against management’s plan. [Capital Markets Day announcement](https://www.pvatepla.com/corporate/investor-relations/news/pva-tepla-hosts-successful-capital-markets-day-2025-and-provides-strategic-outlook/) **€43 is not a downside floor, and €173 is not a central forecast.** These scenarios need re-underwriting against the latest financials before being adopted as current targets. None is a prediction of where a short squeeze would take the stock. # Finally, the short-interest angle This is the secondary argument: a favourable fundamental reassessment could meet a meaningful short position in a relatively lightly traded stock. Our reconciled disclosed net short estimate is **4.95% of issued capital**, approximately **1.077 million shares-equivalent**. JPMorgan Asset Management UK accounts for **3.43%**, AQR and ActusRayPartners for **0.51% each**, and Connor, Clark & Lunn for **0.50%**. Some higher totals include a stale Citadel position, which we excluded after reviewing the historical disclosures. [Finaristo](https://finaristo.com/short-selling/shorted-companies/pva-tepla-ag), [Federal Gazette](https://www.bundesanzeiger.de/pub/en/nlp) Capital IQ’s **84.5% float** implies approximately **18.38 million float shares**. The working short estimate is therefore about **5.86% of float**, or **12 days of the screenshot’s roughly 90,000-share average daily volume**. That volume figure is rounded and its full venue coverage is unspecified. For scale, suppose **5,000 independent investors hypothetically allocated $5,000 each**. That is $25 million, approximately **€21.57 million** at the 11 September ECB reference rate. At an unchanged €28.50, it represents approximately **757,000 shares**, **4.12% of float**, or **8.4 normal-volume days**. At **10,000 investors**, those numbers double to approximately **1.513 million shares**, **8.23% of float**, and **16.8 normal-volume days**. There is no evidence that this inflow is coming; it is a fully funded ordinary-share purchasing-capacity calculation, not a forecast of buyers. [ECB](https://www.ecb.europa.eu/stats/policy_and_exchange_rates/euro_reference_exchange_rates/html/index.en.html) If half the reconciled short exposure independently unwound as share purchases, that could add approximately **538,000 shares**. Combined gross buying interest would then reach approximately **1.30–2.05 million shares**, equivalent to **14–23 days of ordinary turnover**. That could matter. It does not guarantee anything. Sellers can emerge, event-day turnover can rise, and a higher price reduces the shares a fixed cash budget can purchase. At €45 average execution, the same $25–50 million buys approximately **479,000–959,000 shares**. # Bottom line I am long because I think PVA has a credible opportunity to build a larger, more profitable inspection business, supported by actual orders rather than AI terminology alone. The central risk is execution. Growing demand must become shipments, margins and cash. If it does, investors may reassess both the earnings outlook and the quality of the business. Short covering could amplify that reassessment.